• Startseite
• 4-6
• Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The

4.9 (95) · € 32.50 · Auf Lager

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer

Cancers, Free Full-Text

PDF) Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper

PDF) Overall Survival with Palbociclib and Fulvestrant in Women with HRþ/ HER2¯ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors?

Cancers, Free Full-Text

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The

Cureus, Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival - ScienceDirect

Determinants of response to CDK4/6 inhibitors in the real-world setting

Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review